Biocon Ltd
Biocon Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Biosimilars are expected to scale meaningfully in the second half of FY '27 and into FY '28 with several new product launches supporting growth and operating leverage. Biosimilars revenue expected to scale meaningfully in the second half of FY '27 and onward, driven by new product launches and expanded markets.
From Biocon Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Biosimilars are expected to scale meaningfully in the second half of FY '27 and into FY '28 with several new product launches supporting growth and operating leverage.
- Insulin franchise has crossed $300 million globally and is expected to grow further with expanded capacity coming into play from the second half of FY '27.
- Generic business will see growth supported both by scale-up of existing products and new approvals, leading to margin improvement as utilization of state-of-the-art facilities increases.
- The U.S. biosimilar business share is growing, currently about 40% of total with a long-term stable mix expected between North America (40%), Europe and Japan/Australia (35%), and emerging markets (25%).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Biocon Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The heavy phase of capital investment is largely complete, with major investments behind the company (Page 5).
- Recent doubling of Malaysia capacity for drug substance and drug product; drug product line 2 is being qualified and will be operational soon, drug substance doubling expected by end of FY '26 (Page 15).
- Minor debottlenecking possible at Bangalore; no large greenfield capex needed currently (Page 15).
- Focus going forward is on execution, operating leverage, and profitable scaling rather than large new capital expenditures (Page 19).
- Capital allocation priorities are on sustaining profitable growth and improving utilization rather than significant new capex (Page 19).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Biocon Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Biocon Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹4.5K Cr, net profit ₹199 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Biocon's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Biocon Ltd Q4 FY26 results?
Biosimilars are expected to scale meaningfully in the second half of FY '27 and into FY '28 with several new product launches supporting growth and operating leverage. Biosimilars revenue expected to scale meaningfully in the second half of FY '27 and onward, driven by new product launches and expanded markets.
What is Biocon Ltd share price analysis?
Biocon Ltd currently shows a neutral. The stock trades at a P/E of 95.3 with a market cap of ₹69,295 Cr. Investors should review the full earnings analysis for detailed insights.
Is Biocon Ltd planning capital expenditure?
The heavy phase of capital investment is largely complete, with major investments behind the company (Page 5).
Keep Biocon Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.